Contract

Batch manufacture of high titer/titre GMP (U.S.A.) compliant lentiviral vector for FDA approval

  • University Of Edinburgh

F03: Contract award notice

Notice identifier: 2025/S 000-080811

Procurement identifier (OCID): ocds-h6vhtk-0568ca

Published 8 December 2025, 5:13pm



Section one: Contracting authority

one.1) Name and addresses

University Of Edinburgh

Charles Stewart House, 9-16 Chambers Street

Edinburgh

EH1 1HT

Email

jpike2@ed.ac.uk

Telephone

+44 1316502759

Country

United Kingdom

NUTS code

UKM75 - Edinburgh, City of

Internet address(es)

Main address

http://www.ed.ac.uk

Buyer's address

https://www.publiccontractsscotland.gov.uk/search/Search_AuthProfile.aspx?ID=AA00107

one.2) Information about joint procurement

The contract is awarded by a central purchasing body

one.4) Type of the contracting authority

Body governed by public law

one.5) Main activity

Education


Section two: Object

two.1) Scope of the procurement

two.1.1) Title

Batch manufacture of high titer/titre GMP (U.S.A.) compliant lentiviral vector for FDA approval

Reference number

EC1057

two.1.2) Main CPV code

  • 33600000 - Pharmaceutical products

two.1.3) Type of contract

Supplies

two.1.4) Short description

We are planning a phase I/II clinical trial to treat a rare genetic disease that causes

progressive dementia in children. Our therapy will use autologous CD34+ haematopoietic

stem progenitor cells (HSPCs) which are modified ex vivo with LVV to express

supraphysiologic levels of a secreted enzyme.

In order to progress this therapy, we require a high titre LVV produced to good

manufacturing practice (GMP) standard. The supplier must have extensive previous

experience manufacturing LVVs to this specification which have achieved regulatory

approval for phase I/II clinical trials, ideally for use in human CD34+ HSPC transduction.

The QC defined must be performed in compliance with FDA regulations. The product of

the initial delivery will be delivered directly to the University of California, LA, USA.

Note that throughout the document the British spelling ‘Titre’ has been used; this is

analogous to the American English term ‘Titer’ and the spellings may be used

interchangeably.

The University anticipates initially awarding for;

- Manufacture of concentrated lentiviral vector (LVV) from a 30L viral harvest

- Such award to include any warranties on quality, product replacement (for spoilage),

transport, and other supplier project costs such as (but not limited to) quality control

testing and audit.

The cost estimate of the procurement reflects the anticipated cost of the initial

requirement plus contingency, for (for example but not limited to), 1. Scope extension, 2.

Additional ad-hoc delivery to support further trials.

The time frame of the agreement – 3 years, reflects an initial delivery period expected to

be no longer than 12 months post signature, and the option to buy additional deliveries for

two years thereafter. The University may award additional deliveries to the awarded

supplier via the Negotiated Procedure Without Prior Call for Competition.

For transparency we have a budget appetite of approximately USD560k for the delivery of

the initial services. We may review this estimate from time to time.

Having posted this notice we reserve the right to repost any subsequent notice (including

if the ultimate procurement procedure is re-run) under reduced timescales as set out in

the regulations.

two.1.6) Information about lots

This contract is divided into lots: No

two.1.7) Total value of the procurement (excluding VAT)

Value excluding VAT: 586,904 USD

two.2) Description

two.2.3) Place of performance

NUTS codes
  • US - United States
  • UKM75 - Edinburgh, City of
Main site or place of performance

Product is to be delivered to University of California, Los Angeles, U.S.A.

Contracting party University of Edinburgh is in Edinburgh, Scotland, UK

two.2.4) Description of the procurement

See procurement documentation for all un-abridged description.

DEFINITIONS

FDA is the U.S Food and Drug Administration (FDA); the regulator for new clinical drugs

GMP means ‘Good Manufacturing Practice’; U.S.A.

IND is an “Investigational New Drug Application”; a request to the FDA to be permitted to

administer a new prototype drug on human patients for research purposes

Lentiviral vector (LVV) is a type of virus (retrovirus) that inserts its DNA into the cells of

the organism/person it infects.

Plasmid is a small DNA molecule which stores non-chromosomal DNA.

Must-have capabilities

- Able to produce a 30L harvest of unconcentrated LVV-containing supernatant following

transduction of 293T cells from a certified Master Cell Bank with genome and packaging

plasmids supplied by the University

- Able to concentrate this supernatant by a factor of approx. 100-200x to produce a

concentrated high titre LVV

- The supplier must have extensive prior experience of such manufacture and have

achieved numerous regulatory approvals for use of their LVV products in phase I/II clinical

trials. This is critical to ensure there is confidence that the supplier product will be

acceptable and well-received for regulatory approval.

o 10 years prior experience of manufacturing GMP-compliant LVV products

o Achieved minimum of 50 prior regulatory approvals (ideally FDA) of GMP-compliant

LVV products

- Supplied should follow all relevant legislation applicable to this engagement including in

their location/s of manufacture, and the State of California, USA

- The supplier should demonstrate a manufacturing process which is compliant with GMP

and that gives high confidence of their ability to deliver a high quality, compliant, product.

- For the purposes of greater transparency, collaboration and regulatory traceability and

accountability we require a direct relationship with the manufacturing entity/lead and

therefore bids proposed by an entity acting solely as a reseller/distributor will unfortunately

not be acceptable for this requirement. It is our expectation that the bidder undertakes the

manufacturing; however other functions like Quality Control may be undertaken by

subcontractors providing that the bidder takes full ultimate responsibility for delivery of the

contract.

- The supplier should demonstrate a reasonable and practicable solution for logistical

delivery of the product.

- For transparency we have a budget appetite of approximately USD560k for the delivery

of the initial services. We may review this estimate from time to time.

Desirable criteria

- It is desirable that the supplier can complete end to end delivery of initial requirement

(including manufacture, quality control and regulatory pack preparation), within 12 months

or faster from contract signature. Fast delivery times are desirable for the project.

- It is desirable that the supplier takes full accountability for the transport of the product

from the site of manufacture to UCLA.

Quality control (‘QC’);

This will require comprehensive GMP compliance QC to be performed:

Supplier will be required to provide details of the GMP-compliant manufacturing process

Intellectual property

For avoidance of doubt; the intellectual property (“IP”) the University provides during the

project in relation to the product specification will remain vested in the University and its

licensors and nothing in the awarded contract shall constitute granting a license, creating

a joint endeavour, creating joint IP, or otherwise constituting a license or transfer of IP to

the Supplier, that would entitle the Supplier to take any action utilising that IP beyond the

bounds of the Services which will be agreed between the University and Supplier

pursuant of this tender.

two.2.5) Award criteria

Quality criterion - Name: Suitability to fulfil requirement / Weighting: 50

Cost criterion - Name: Total cost / Weighting: 50

two.2.11) Information about options

Options: Yes

Description of options

The time frame of the agreement – 3 years, reflects an initial delivery period expected to

be no longer than 12 months post signature, and the option to buy additional deliveries for

two years thereafter. The University may award additional deliveries to the awarded

supplier via the Negotiated Procedure Without Prior Call for Competition.

two.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No


Section four. Procedure

four.1) Description

four.1.1) Type of procedure

Competitive procedure with negotiation

four.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

four.2) Administrative information

four.2.1) Previous publication concerning this procedure

Notice number: 2025/S 000-044163


Section five. Award of contract

Contract No

EC1057

A contract/lot is awarded: Yes

five.2) Award of contract

five.2.1) Date of conclusion of the contract

7 November 2025

five.2.2) Information about tenders

Number of tenders received: 1

Number of tenders received from SMEs: 0

Number of tenders received from tenderers from other EU Member States: 0

Number of tenders received from tenderers from non-EU Member States: 1

Number of tenders received by electronic means: 1

The contract has been awarded to a group of economic operators: No

five.2.3) Name and address of the contractor

Indiana University

1024 East 3rd Street, Room 132

Bloomington

47405

Telephone

+001 3172786518

Country

United States

NUTS code
  • US - United States
The contractor is an SME

No

five.2.4) Information on value of contract/lot (excluding VAT)

Total value of the contract/lot: 586,904 USD


Section six. Complementary information

six.3) Additional information

(SC Ref:817966)

six.4) Procedures for review

six.4.1) Review body

Edinburgh Sheriff Court

Edinburgh

Country

United Kingdom